Over the past 5 years, several therapies have been developed that have proven to be effective for patients with multiple myeloma. The FDA has approved several 3-drug regimens, including the combination of immunomodulatory drugs (IMiDs), a proteasome inhibitor, and dexamethasone, which is now the standard of care in the first-line setting.
At this time, there are a variety of treatment options available for patients with multiple myeloma. While the availability of different treatment regimens has been a major advance in the field, more research is still necessary, as the majority of patients with multiple myeloma become refractory at some point and require alternative treatment options. Some of the latest research in the field revolves around CAR T cells, which are showing significant initial responses. More research is still necessary to determine the durability of these responses.
In an interview with Targeted Oncology during the2nd Annual Live Medical Crossfire: Hematologic Malignancies meeting, Alexander M. Lesokhin, MD, assistant attending physician in the Department of Medicine and Myeloma Service at Memorial Sloan Kettering Cancer Center, discussed the current treatment landscape of multiple myeloma and where he predicts the field will be in the next decade. He also shared his thoughts on the current research in CAR T-cell therapy.
Read more: https://www.targetedonc.com/news/immune-approaches-hold-great-promise-in-myeloma-expert-says